Monster Beverage Corp (MNST) concluded trading on Thursday at a closing price of $49.52, with 5.19 million shares of worth about $256.8 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.49% during that period and on February 13, 2025 the price saw a gain of about 2.80%. Currently the company’s common shares owned by public are about 972.45M shares, out of which, 690.78M shares are available for trading.
Stock saw a price change of 6.95% in past 5 days and over the past one month there was a price change of -1.16%. Year-to-date (YTD), MNST shares are showing a performance of -5.78% which decreased to -11.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $43.32 but also hit the highest price of $61.22 during that period. The average intraday trading volume for Monster Beverage Corp shares is 5.53 million. The stock is currently trading 2.55% above its 20-day simple moving average (SMA20), while that difference is down -2.13% for SMA50 and it goes to -3.19% lower than SMA200.
Monster Beverage Corp (NASDAQ: MNST) currently have 972.45M outstanding shares and institutions hold larger chunk of about 64.21% of that.
The stock has a current market capitalization of $48.16B and its 3Y-monthly beta is at 0.74. PE ratio of stock for trailing 12 months is 31.81, while it has posted earnings per share of $1.56 in the same period. Its PEG reads 3.25 and has Quick Ratio of 2.51 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MNST, volatility over the week remained 2.28% while standing at 2.27% over the month.
Stock’s fiscal year EPS is expected to rise by 6.05% while it is estimated to increase by 12.80% in next year. EPS is likely to shrink at an annualized rate of 9.80% for next 5-years, compared to annual growth of 11.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on December 19, 2024 offering an Underperform rating for the stock and assigned a target price range of between $46 and $45 to it. On November 12, 2024, Argus Reiterated their recommendations, while on November 11, 2024, TD Cowen Reiterated their ratings for the stock with a price target of $55. Stock get a Neutral rating from UBS on November 08, 2024.
